Expression and Clinical Significance of High-Mobility Group AT-hook 2 (HMGA2) in Osteosarcoma

Overview

Journal Orthop Surg

Specialty Orthopedics

Date 2022 Apr 7

PMID 35388973

Authors

Juncheng Cui

Dylan Dean

Francis J Hornicek

Guoliang Yi

Zhenfeng Duan

Affiliations

Soon will be listed here.

Abstract

Objective: Although high-mobility group AT-hook 2 (HMGA2) has been shown to have crucial roles in the pathogenesis and metastasis of various malignancies, its expression and significance in osteosarcoma remain unknown. Here we evaluate the expression, clinical prognostic value, and overall function of HMGA2 in osteosarcoma.

Methods: Sixty-nine osteosarcoma patient specimens within a tissue microarray (TMA) were analyzed by immunohistochemistry for HMGA2 expression. Demographics and clinicopathological information including age, gender, tumor location, metastasis, recurrence, chemotherapy response, follow-up time, and disease status were also collected. After validation of expression, we determined whether there was a correlation between HMGA2 expression and patient clinicopathology. HMGA2 expression was also evaluated in osteosarcoma cell lines and patient tissues by Western blot, we analyzed the expression of HMGA2 in the human osteosarcoma cell lines MG63, 143B, U2OS, Saos-2, MNNG/HOS, and KHOS. HMGA2-specific siRNA and clonogenic assays were then used to determine the effect of HMGA2 inhibition on osteosarcoma cell proliferation, growth, and chemosensitivity.

Results: HMGA2 expression was elevated in the osteosarcoma patient specimens and human osteosarcoma cell lines. HMGA2 was differentially expressed in human osteosarcoma cell lines. Specifically, a relatively high expression of HMGA2 was present in KHOS, MNNG/HOS, 143B and a relatively low expression was in MG63, U2OS as well as Saos-2. HMGA2 expression is correlated with metastasis and shorter overall survival. High HMGA2 expression is an independent predictor of poor osteosarcoma prognosis. There was no significant correlation between HMGA2 expression and the age, gender, or tumor site of the patient. HMGA2 expression is predominantly within the nucleus. The expression of HMGA2 also directly correlated to neoadjuvant chemoresistance. There was a significant reduction of HMGA2 expression in the siRNA transfection group. After the use of siRNA, the proliferation of osteosarcoma cells is decreased and the chemosensitivity of osteosarcoma cells is significantly increased.

Conclusion: Our study supports HMGA2 as a potential prognostic biomarker and therapeutic target in osteosarcoma.

References

Wang X, Liu X, Li A, Chen L, Lai L, Lin H . Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clin Cancer Res. 2011; 17(8):2570-80. PMC: 3079060. DOI: 10.1158/1078-0432.CCR-10-2542. View

Zhang S, Mo Q, Wang X . Oncological role of HMGA2 (Review). Int J Oncol. 2019; 55(4):775-788. DOI: 10.3892/ijo.2019.4856. View

Xu X, Wang Y, Deng H, Liu C, Wu J, Lai M . HMGA2 enhances 5-fluorouracil chemoresistance in colorectal cancer via the Dvl2/Wnt pathway. Oncotarget. 2018; 9(11):9963-9974. PMC: 5839414. DOI: 10.18632/oncotarget.24133. View

Wend P, Runke S, Wend K, Anchondo B, Yesayan M, Jardon M . WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol Med. 2013; 5(2):264-79. PMC: 3569642. DOI: 10.1002/emmm.201201320. View

Goodwin G . The high mobility group protein, HMGI-C. Int J Biochem Cell Biol. 1998; 30(7):761-6. DOI: 10.1016/s1357-2725(98)00016-8. View

Wei R, Thanindratarn P, Dean D, Hornicek F, Guo W, Duan Z . Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma. J Orthop Res. 2020; 38(9):1952-1964. DOI: 10.1002/jor.24659. View

Huang B, Yang J, Cheng Q, Xu P, Wang J, Zhang Z . Prognostic Value of HMGA2 in Human Cancers: A Meta-Analysis Based on Literatures and TCGA Datasets. Front Physiol. 2018; 9:776. PMC: 6028738. DOI: 10.3389/fphys.2018.00776. View

Marquis M, Beaubois C, Lavallee V, Abrahamowicz M, Danieli C, Lemieux S . High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. Blood Cancer J. 2018; 8(8):68. PMC: 6066481. DOI: 10.1038/s41408-018-0103-6. View

Hombach-Klonisch S, Kalantari F, Medapati M, Natarajan S, Krishnan S, Kumar-Kanojia A . HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells. Mol Oncol. 2018; 13(2):153-170. PMC: 6360374. DOI: 10.1002/1878-0261.12390. View

10.

Bustin M, Reeves R . High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol. 1996; 54:35-100. DOI: 10.1016/s0079-6603(08)60360-8. View

11.

Dong J, Wang R, Ren G, Li X, Wang J, Sun Y . HMGA2-FOXL2 Axis Regulates Metastases and Epithelial-to-Mesenchymal Transition of Chemoresistant Gastric Cancer. Clin Cancer Res. 2017; 23(13):3461-3473. DOI: 10.1158/1078-0432.CCR-16-2180. View

12.

Sampo M, Koivikko M, Taskinen M, Kallio P, Kivioja A, Tarkkanen M . Incidence, epidemiology and treatment results of osteosarcoma in Finland - a nationwide population-based study. Acta Oncol. 2011; 50(8):1206-14. DOI: 10.3109/0284186X.2011.615339. View

13.

Morishita A, Zaidi M, Mitoro A, Sankarasharma D, Szabolcs M, Okada Y . HMGA2 is a driver of tumor metastasis. Cancer Res. 2013; 73(14):4289-99. PMC: 3715567. DOI: 10.1158/0008-5472.CAN-12-3848. View

14.

Wu H, Zou Q, He H, Liang Y, Lei M, Zhou Q . Long non-coding RNA PCAT6 targets miR-204 to modulate the chemoresistance of colorectal cancer cells to 5-fluorouracil-based treatment through HMGA2 signaling. Cancer Med. 2019; 8(5):2484-2495. PMC: 6536993. DOI: 10.1002/cam4.1809. View

15.

Kubo T, Shimose S, Fujimori J, Furuta T, Ochi M . Quantitative (201)thallium scintigraphy for prediction of histological response to neoadjuvant chemotherapy in osteosarcoma; systematic review and meta-analysis. Surg Oncol. 2015; 24(3):194-9. DOI: 10.1016/j.suronc.2015.06.009. View

16.

Rietveld C, Cesarini D, Benjamin D, Koellinger P, De Neve J, Tiemeier H . Molecular genetics and subjective well-being. Proc Natl Acad Sci U S A. 2013; 110(24):9692-7. PMC: 3683731. DOI: 10.1073/pnas.1222171110. View

17.

Xiao G, Wang X, Yu Y . CXCR4/Let-7a Axis Regulates Metastasis and Chemoresistance of Pancreatic Cancer Cells Through Targeting HMGA2. Cell Physiol Biochem. 2017; 43(2):840-851. DOI: 10.1159/000481610. View

18.

Dangi-Garimella S, Krantz S, Barron M, Shields M, Heiferman M, Grippo P . Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res. 2010; 71(3):1019-28. PMC: 3076124. DOI: 10.1158/0008-5472.CAN-10-1855. View

19.

Gao X, Dai M, Li Q, Wang Z, Lu Y, Song Z . HMGA2 regulates lung cancer proliferation and metastasis. Thorac Cancer. 2017; 8(5):501-510. PMC: 5582513. DOI: 10.1111/1759-7714.12476. View

20.

Sakata J, Hirosue A, Yoshida R, Kawahara K, Matsuoka Y, Yamamoto T . HMGA2 Contributes to Distant Metastasis and Poor Prognosis by Promoting Angiogenesis in Oral Squamous Cell Carcinoma. Int J Mol Sci. 2019; 20(10). PMC: 6566167. DOI: 10.3390/ijms20102473. View